Proteomic investigating the cooperative lethal effect of EGFR and MDM2 inhibitors on ovarian carcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Archives of biochemistry and biophysics"
DOI: 10.1016/j.abb.2018.04.004
Abstract: With the concept of precision medicine, combining multiple molecular-targeting therapies has brought new approaches to current cancer treatments. Malfunction of the tumor suppressor protein, p53 is a universal hallmark in human cancers. Under normal conditions,… read more here.
Keywords: egfr; mdm2 inhibitors; mdm2; inhibition ... See more keywords
Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Sign Up to like & getrecommendations! Published in 2021 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2021.105427
Abstract: Despite the achieved progress in developing efficient MDM2-p53 protein-protein interaction inhibitors (MDM2 inhibitors), the acquired resistance of tumor cells to such p53 activators posed an argument about the druggability of the pathway. Combination studies disclosed… read more here.
Keywords: mdm2 inhibitors; based mdm2; p53; spirooxindole based ... See more keywords
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.17790
Abstract: Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may be effectively targeted using MDM2 inhibitors. In the… read more here.
Keywords: mdm2 inhibitors; mpm; mdm2; pleural mesothelioma ... See more keywords
MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1000677
Abstract: MDM2 is the principal inhibitor of p53, and MDM2 inhibitors can disrupt the physical interaction between MDM2 and p53. The half-life of p53 is very short in normal cells and tissues, and an uncontrolled increase… read more here.
Keywords: mitochondrial metabolism; mdm2 inhibitors; retinoblastoma; p53 ... See more keywords